Q2 EPS Estimates for Envoy Medical Lowered by HC Wainwright

Envoy Medical, Inc. (NASDAQ:COCH) – Research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for Envoy Medical in a report issued on Wednesday, July 15th. HC Wainwright analyst Y. Chen now expects that the company will earn ($0.09) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $2.50 price target on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Envoy Medical’s Q3 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.29) EPS.

A number of other equities research analysts have also recently weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Envoy Medical in a research report on Friday, April 24th. Zacks Research raised Envoy Medical to a “hold” rating in a report on Wednesday, April 1st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Envoy Medical has a consensus rating of “Hold” and an average price target of $2.50.

Envoy Medical Trading Down 7.7%

Shares of Envoy Medical stock opened at $0.70 on Friday. The company has a fifty day simple moving average of $0.69 and a 200-day simple moving average of $0.68. The stock has a market cap of $53.94 million, a price-to-earnings ratio of -0.69 and a beta of 1.88. Envoy Medical has a 12-month low of $0.36 and a 12-month high of $1.89.

Envoy Medical (NASDAQ:COCH) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.10 million.

Hedge Funds Weigh In On Envoy Medical

A number of hedge funds have recently modified their holdings of the business. DSG Capital Advisors LLC acquired a new position in shares of Envoy Medical in the 1st quarter valued at $416,000. Focus Partners Wealth acquired a new stake in Envoy Medical during the 1st quarter worth $276,000. CIBC Bancorp USA Inc. purchased a new position in Envoy Medical during the 3rd quarter worth $60,000. Finally, Geode Capital Management LLC grew its position in Envoy Medical by 111.3% during the 4th quarter. Geode Capital Management LLC now owns 98,351 shares of the company’s stock worth $65,000 after purchasing an additional 51,813 shares during the last quarter. 8.59% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Envoy Medical

Here are the key news stories impacting Envoy Medical this week:

• Negative Sentiment: HC Wainwright lowered its Q2 2026 EPS estimate for Envoy Medical to ($0.09) from ($0.08) and cut its Q3 2026 EPS estimate to ($0.07) from ($0.06), signaling slightly weaker profitability expectations. Article link
• Neutral Sentiment: The firm still kept a Buy rating and $2.50 price target on COCH, suggesting analysts remain constructive on the longer-term story despite the near-term estimate cuts. Article link
• Neutral Sentiment: HC Wainwright also slightly improved its FY2026 EPS forecast to ($0.29) from ($0.30) and projected FY2027 EPS of ($0.19), indicating losses are expected to narrow over time. Article link

Envoy Medical Company Profile

Envoy Medical (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals.